Antiarrhythmic drug usage and prostate cancer: a population-based cohort study

Li-Ting Kao1,2,*, Chung-Chien Huang3,7, Herring-Ching Lin2,3, Chao-Yuan Huang4,5,6

Even though the relationship between antiarrhythmic drug usage and subsequent prostate cancer (PCA) risk has recently been highlighted, relevant findings in the previous literature are still inconsistent. In addition, very few studies have attempted to investigate the association between sodium channel blockers or potassium channel blockers for arrhythmia and the subsequent PCA risk. Therefore, this cohort study aimed to find the relationship between antiarrhythmic drug usage and the subsequent PCA risk using a large population-based dataset. The data used in this study were derived from the Longitudinal Health Insurance Database 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65,966 beta-blocker users, 23,366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCA. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCA for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84–1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59–1.34), for beta-blocker users was 1.08 (95% CI: 0.96–1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95–1.36), and for digoxin users was 0.89 (95% CI: 0.67–1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCA risk.

Asian Journal of Andrology (2018) 20, 37–42; doi: 10.4103/aja.aja_26_17; published online: 29 August 2017

Keywords: antiarrhythmic drugs; cancer; digoxin; ion channel blocker; prostate cancer

INTRODUCTION
Prostate cancer (PCA) is a prevalent urological malignancy in elderly male populations.1 Even though this disease affected over 899,000 patients and contributed to 258,000 deaths in 2008 worldwide, the actual pathophysiology and risk factors of PCA remain unclear.23 Therefore, finding protective factors, exploring risk factors, and further developing prevention strategies for PCA are recognized as important public health issues.

To date, increasing experimental evidence has supported that channels for potassium, sodium, and calcium are frequently overexpressed in PCA cells, and these ion channels are thought to regulate PCA cell proliferation and metastasis.4–10 In addition, previous studies reported that cardiac glycosides which inhibit Na+/K+ ATPase and contribute to elevated intracellular calcium concentrations can affect prostate-specific antigen (PSA) levels and suppress tumor growth.11,12 Thus, many studies supposed that ion channel blockers and cardiac glycosides, which were developed for other indications, including arrhythmia and epilepsy, could potentially be novel therapeutic strategies against PCs.13,14

Recently, as many of the elderly are regularly using antiarrhythmic drugs (including sodium channel blockers, potassium channel blockers, beta-blockers, calcium channel blockers, and digoxin), the relationship between antiarrhythmic drug usage and the subsequent PCA risk has been highlighted. Nevertheless, very few studies have investigated the subsequent PCA risk in sodium channel blocker users or potassium channel blocker users.15,16 Most of the literature only attempted to find the PCA risk in beta-blocker users, calcium channel blocker users, and digoxin users. For instance, some prior studies showed that beta-blocker users, calcium channel blocker users, and digoxin users might have a decreased risk of PCA.17–20 Other studies observed that the use of beta-blockers or calcium channel blockers was not associated with a PCA risk.15,21–24 Conversely, recent meta-analyses presented increased risks of PCA in beta-blocker users and calcium channel blocker users.25 Accordingly, relevant findings in previous studies are still inconclusive today. Consequently, this retrospective cohort study aimed to explore the associations between the use of different types of antiarrhythmic drugs and the subsequent PCA risk using a large population-based dataset in Taiwan, China.

PATIENTS AND METHODS

Database
This retrospective cohort study used medical records derived from the Longitudinal Health Insurance Database 2005 (LHID2005, 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65,966 beta-blocker users, 23,366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCA. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCA for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84–1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59–1.34), for beta-blocker users was 1.08 (95% CI: 0.96–1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95–1.36), and for digoxin users was 0.89 (95% CI: 0.67–1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCA risk.

Asian Journal of Andrology (2018) 20, 37–42; doi: 10.4103/aja.aja_26_17; published online: 29 August 2017

Keywords: antiarrhythmic drugs; cancer; digoxin; ion channel blocker; prostate cancer

INTRODUCTION
Prostate cancer (PCA) is a prevalent urological malignancy in elderly male populations.1 Even though this disease affected over 899,000 patients and contributed to 258,000 deaths in 2008 worldwide, the actual pathophysiology and risk factors of PCA remain unclear.23 Therefore, finding protective factors, exploring risk factors, and further developing prevention strategies for PCA are recognized as important public health issues.

To date, increasing experimental evidence has supported that channels for potassium, sodium, and calcium are frequently overexpressed in PCA cells, and these ion channels are thought to regulate PCA cell proliferation and metastasis.4–10 In addition, previous studies reported that cardiac glycosides which inhibit Na+/K+ ATPase and contribute to elevated intracellular calcium concentrations can affect prostate-specific antigen (PSA) levels and suppress tumor growth.11,12 Thus, many studies supposed that ion channel blockers and cardiac glycosides, which were developed for other indications, including arrhythmia and epilepsy, could potentially be novel therapeutic strategies against PCs.13,14

Recently, as many of the elderly are regularly using antiarrhythmic drugs (including sodium channel blockers, potassium channel blockers, beta-blockers, calcium channel blockers, and digoxin), the relationship between antiarrhythmic drug usage and the subsequent PCA risk has been highlighted. Nevertheless, very few studies have investigated the subsequent PCA risk in sodium channel blocker users or potassium channel blocker users.15,16 Most of the literature only attempted to find the PCA risk in beta-blocker users, calcium channel blocker users, and digoxin users. For instance, some prior studies showed that beta-blocker users, calcium channel blocker users, and digoxin users might have a decreased risk of PCA.17–20 Other studies observed that the use of beta-blockers or calcium channel blockers was not associated with a PCA risk.15,21–24 Conversely, recent meta-analyses presented increased risks of PCA in beta-blocker users and calcium channel blocker users.25 Accordingly, relevant findings in previous studies are still inconclusive today. Consequently, this retrospective cohort study aimed to explore the associations between the use of different types of antiarrhythmic drugs and the subsequent PCA risk using a large population-based dataset in Taiwan, China.

PATIENTS AND METHODS

Database
This retrospective cohort study used medical records derived from the Longitudinal Health Insurance Database 2005 (LHID2005, 2005, Taiwan, China. We respectively identified 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65,966 beta-blocker users, 23,366 calcium channel blockers users, and 7031 digoxin users as the study cohorts. The matched comparison cohorts (one comparison subject for each antiarrhythmic drug user) were selected from the same dataset. Each patient was tracked for a 5-year period to define those who were subsequently diagnosed with PCA. After adjusting for sociodemographic characteristics, comorbidities, and age, Cox proportional hazard regressions found that the hazard ratio (HR) of subsequent PCA for sodium channel blocker users was 1.12 (95% confidence interval [CI]: 0.84–1.50), for potassium channel blocker users was 0.89 (95% CI: 0.59–1.34), for beta-blocker users was 1.08 (95% CI: 0.96–1.22), for calcium channel blocker users was 1.14 (95% CI: 0.95–1.36), and for digoxin users was 0.89 (95% CI: 0.67–1.18), compared to their matched nonusers. We concluded that there were no statistical associations between different types of antiarrhythmic drug usage and subsequent PCA risk.

Asian Journal of Andrology (2018) 20, 37–42; doi: 10.4103/aja.aja_26_17; published online: 29 August 2017

Keywords: antiarrhythmic drugs; cancer; digoxin; ion channel blocker; prostate cancer

INTRODUCTION
Prostate cancer (PCA) is a prevalent urological malignancy in elderly male populations.1 Even though this disease affected over 899,000 patients and contributed to 258,000 deaths in 2008 worldwide, the actual pathophysiology and risk factors of PCA remain unclear.23 Therefore, finding protective factors, exploring risk factors, and further developing prevention strategies for PCA are recognized as important public health issues.

To date, increasing experimental evidence has supported that channels for potassium, sodium, and calcium are frequently overexpressed in PCA cells, and these ion channels are thought to regulate PCA cell proliferation and metastasis.4–10 In addition, previous studies reported that cardiac glycosides which inhibit Na+/K+ ATPase and contribute to elevated intracellular calcium concentrations can affect prostate-specific antigen (PSA) levels and suppress tumor growth.11,12 Thus, many studies supposed that ion channel blockers and cardiac glycosides, which were developed for other indications, including arrhythmia and epilepsy, could potentially be novel therapeutic strategies against PCs.13,14

Recently, as many of the elderly are regularly using antiarrhythmic drugs (including sodium channel blockers, potassium channel blockers, beta-blockers, calcium channel blockers, and digoxin), the relationship between antiarrhythmic drug usage and the subsequent PCA risk has been highlighted. Nevertheless, very few studies have investigated the subsequent PCA risk in sodium channel blocker users or potassium channel blocker users.15,16 Most of the literature only attempted to find the PCA risk in beta-blocker users, calcium channel blocker users, and digoxin users. For instance, some prior studies showed that beta-blocker users, calcium channel blocker users, and digoxin users might have a decreased risk of PCA.17–20 Other studies observed that the use of beta-blockers or calcium channel blockers was not associated with a PCA risk.15,21–24 Conversely, recent meta-analyses presented increased risks of PCA in beta-blocker users and calcium channel blocker users.25 Accordingly, relevant findings in previous studies are still inconclusive today. Consequently, this retrospective cohort study aimed to explore the associations between the use of different types of antiarrhythmic drugs and the subsequent PCA risk using a large population-based dataset in Taiwan, China.
Taiwan, China). This database consists of claims data for 1 million individuals randomly selected from the National Health Insurance (NHI, Taiwan, China) program in 2005 \((n = 25.68\text{ million})\). The NHI (Taiwan, China) program was founded in 1995. It provides comprehensive and affordable medical services for over 99% of citizens from Taiwan, China. The LHID2005 consists of de-identified secondary data released to the public for academic purposes and was exempted from full review following consultation with the Taipei Medical University Institutional Review Board (TMU-JIRB 201612057), Taiwan, China.

**Study sample**

This population-based cohort study identified patients who received a prescription of antiarrhythmic drugs during an ambulatory care visit from 1 January 2001 to 31 December 2008. Selected patients were categorized as having been exposed to sodium channel blockers (disopyramide, quinidine, flecainide, lidocaine, procainamide, propafenone, phenytoin, mexiletine, and prajmaline), potassium channel blockers (amiodarone, dronedarone, and sotalol), beta-blockers (atenolol, bisoprolol, carvedilol, esmolol, metoprolol, propranolol, and timolol), calcium channel blockers (diltiazem and verapamil), or digoxin. The date of the first ambulatory care visit for receiving each antiarrhythmic drug was identified as the index date for each study participant. We then excluded female patients, to limit the study to the male population. Patients aged <40 years were also excluded from this study, because very few patients receive antiarrhythmic drugs in that age group. We further excluded those patients who had been diagnosed with PCa (ICD-9-CM code 185) prior to the index date. Finally, 9988 sodium channel blocker users, 3663 potassium channel blocker users, 65,966 beta-blocker users, 23,366 calcium channel blocker users, and 7031 digoxin users were identified as study cohorts in this study.

The matched comparison cohorts (one comparison subject per patient who received an antiarrhythmic drug) were selected from the remaining beneficiaries of the LHID2005. The comparison cohorts were selected by matching male patients receiving an antiarrhythmic drug in terms of age group (40–49 years and ≥50 years) and year of the index date. For the comparison cohorts, the year of the index date was simply a matched year in which the comparison subjects had a medical utilization. We assured that none of the comparison subjects had a medical history of PCa prior to the index date. Ultimately, 9988 sodium channel blocker nonusers, 3663 potassium channel blocker nonusers, 65,966 beta-blocker nonusers, 23,366 calcium channel blocker nonusers, and 7031 digoxin nonusers were defined as comparison cohorts in this study.

**Outcome measures**

This retrospective cohort study attempted to investigate the association between the use of antiarrhythmic drugs and subsequent PCa. Each patient was individually tracked for a 5-year period from their index date to define those who were subsequently diagnosed with PCa (ICD-9-CM code 185, malignant neoplasm of the prostate).

**Statistical analysis**

The SAS System for Windows (version 9.2, SAS Institute, Cary, NC, USA) was used to perform all analyses in this study. Chi-squared tests were conducted to investigate differences in monthly income, geographic location (Northern, Central, Eastern, and Southern Taiwan, China), urbanization level (five levels, with level 1 being the most urbanized and level 5 being the least), hypertension, hyperlipidemia, and diabetes between the study cohorts and matched comparison cohorts. Conditional Cox proportional hazard regression analyses were used to evaluate the hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for PCa during the 5-year study period between the study cohorts and their matched comparison cohorts. In addition, the adjustments were made for patients’ monthly income, geographical region, urbanization level, age, hypertension, diabetes, hyperlipidemia, and obesity. We used a two-sided \( P = 0.05 \) to define statistical significance in this study.

**RESULTS**

Distributions of demographic characteristics and medical comorbidities between patients who received antiarrhythmic drugs and their matched comparison subjects are shown in Table 1 and 2. Table 1 and 2 show that there were statistical differences between sodium channel blocker users, beta-blocker users, digoxin users, and their matched nonusers in the distributions of monthly income, geographic location, urbanization level, hypertension, hyperlipidemia, diabetes, and obesity (all \( P < 0.001 \)). Table 1 also shows that there were statistical differences in urbanization level (\( P = 0.041 \)), hypertension (\( P < 0.001 \)), hyperlipidemia (\( P < 0.001 \)), and diabetes (\( P < 0.001 \)) between potassium channel blocker users and their matched nonusers, respectively. However, there was no difference in monthly income or geographic location between potassium channel blocker users and their matched nonusers. In addition, there were statistical differences between calcium channel blocker users and matched nonusers in terms of monthly income (\( P = 0.044 \)), geographical location (\( P < 0.001 \)), urbanization level (\( P < 0.001 \)), hypertension (\( P < 0.001 \)), hyperlipidemia (\( P < 0.001 \)), and diabetes (\( P < 0.001 \)).

Table 3 shows the incidence rates for PCa among the sampled patients. The findings indicate that the incidence rates of PCa per 1000 person-years within the 5-year follow-up period were 2.65 (95% CI: 2.21–3.14) and 1.93 (95% CI: 1.57–2.36) for sodium channel blocker users and matched nonusers, respectively. Moreover, incidence rates of PCa per 1000 person-years within the 5-year study period were 3.36 (95% CI: 2.57–4.32) and 3.08 (95% CI: 2.32–3.99) for potassium channel blocker users and their matched nonusers, respectively. The Cox proportional hazard regression analyses further revealed that the adjusted HR of subsequent PCa for sodium channel blocker users was 1.12 (95% CI: 0.84–1.50, \( P = 0.423 \)) compared to matched nonusers after adjusting for demographic characteristics and comorbidities. The adjusted HR was 0.89 (95% CI: 0.59–1.34, \( P = 0.585 \)) for potassium channel blocker users compared to the matched nonusers (Table 3).

Table 4 reveals that incidence rates per 1000 person-years for subsequent PCa in beta-blocker users and matched nonusers were 2.19 (95% CI: 2.04–2.36) and 1.81 (95% CI: 1.66–1.96), respectively. Incidence rates of PCa per 1000 person-years were 3.07 (95% CI: 2.76–3.41) and 2.18 (95% CI: 1.92–2.46) for calcium channel blocker users and their matched nonusers, respectively. Table 4 also presents that the incidence rates of PCa per 1000 person-years were 3.65 (95% CI: 3.04–4.34) and 3.12 (95% CI: 2.56–3.76) for digoxin users and their matched nonusers, respectively. In addition, the HRs for subsequent PCa in beta-blocker users, calcium channel blocker users, and digoxin users compared to their matched nonusers are also shown in Table 4. The adjusted HRs for subsequent PCa in beta-blocker users, calcium channel blocker users, and digoxin users were 1.08 (95% CI: 0.96–1.22, \( P = 0.212 \)), 1.14 (95% CI: 0.95–1.36, \( P = 0.162 \)), and 0.89 (95% CI: 0.67–1.18, \( P = 0.406 \)) compared to their matched nonusers, respectively.
Table 1: Demographic characteristics of sampled patients who received antiarrhythmic drugs and their matched comparison patients

| Variable                      | Sodium channel blockers (Class I antiarrhythmic drugs) | Potassium channel blockers (Class III antiarrhythmic drugs) |
|-------------------------------|--------------------------------------------------|---------------------------------------------------|
|                               | Users (n=3663) | Nonusers (n=3663) | P      | Users (n=3663) | Nonusers (n=3663) | P      |
| Age (year, n [%])             |                   |                   |       |                   |                   |       |
| 40–49                         | 2037 (20.4)      | 2037 (20.4)       | >0.999| 358 (9.8)        | 358 (9.8)         | >0.999|
| ≥50                           | 7951 (79.6)      | 7951 (79.6)       |       | 3305 (90.2)      | 3305 (90.2)       |       |
| Monthly income (US Dollar, n [%]) |               |                   |       |                   |                   |       |
| 1–530                         | 4757 (47.6)      | 4558 (45.6)       | <0.001| 1916 (52.3)      | 1879 (51.3)       | 0.667 |
| 530–830                       | 3554 (35.6)      | 3464 (34.7)       |       | 1243 (33.9)      | 1276 (34.8)       |       |
| ≥830                          | 1677 (16.8)      | 1966 (19.7)       |       | 504 (13.8)       | 508 (13.9)        |       |
| Geographical region,* n [%]   |                   |                   |       |                   |                   |       |
| Northern                      | 3927 (39.3)      | 4684 (46.9)       | <0.001| 1571 (42.9)      | 1662 (45.4)       | 0.148 |
| Central                       | 2813 (28.2)      | 2246 (22.5)       |       | 888 (24.2)       | 872 (23.8)        |       |
| Southern                      | 2881 (28.8)      | 2803 (28.1)       |       | 1099 (30.0)      | 1024 (28.0)       |       |
| Eastern                       | 367 (3.7)        | 255 (2.6)         |       | 105 (2.9)        | 105 (2.9)         |       |
| Urbanization level, n [%]     |                   |                   |       |                   |                   |       |
| 1 (most urbanized)            | 2313 (23.2)      | 2885 (28.9)       | <0.001| 976 (26.6)       | 986 (26.9)        | 0.041 |
| 2                             | 2813 (28.2)      | 2612 (26.2)       |       | 1041 (28.4)      | 937 (25.6)        |       |
| 3                             | 1585 (15.9)      | 1559 (15.6)       |       | 529 (14.4)       | 556 (15.2)        |       |
| 4                             | 1772 (17.7)      | 1552 (15.5)       |       | 593 (16.2)       | 595 (16.2)        |       |
| 5 (least urbanized)           | 1505 (15.1)      | 1380 (13.8)       |       | 524 (14.3)       | 589 (16.1)        |       |
| Comorbidities, n [%]          |                   |                   |       |                   |                   |       |
| Hypertension                  | 5217 (52.2)      | 2091 (20.9)       | <0.001| 2342 (63.9)      | 847 (23.1)        | <0.001|
| Diabetes                      | 2227 (22.3)      | 1255 (12.6)       | <0.001| 968 (26.4)       | 486 (13.3)        | <0.001|
| Hyperlipidemia                | 2056 (20.6)      | 1144 (11.5)       | <0.001| 943 (25.7)       | 466 (12.7)        | <0.001|
| Obesity                       | 155 (1.6)        | 90 (0.9)          | <0.001| 68 (1.9)         | 21 (0.6)          | <0.001|

aTaiwan, China

Table 2: Demographic characteristics of sampled patients who received beta-blockers, calcium channel blockers, or digoxin and their matched comparison patients

| Variable                      | Beta-blockers (Class II antiarrhythmic drugs) | Calcium channel blockers (Class IV antiarrhythmic drugs) | Digoxin |
|-------------------------------|------------------------------------------------|---------------------------------------------------|---------|
|                               | Users (n=23 366) | Nonusers (n=23 366) | P      | Users (n=7031) | Nonusers (n=7031) | P      |
| Age (year, n [%])             |                   |                   |       |                   |                   |       |
| 40–49                         | 18542 (28.1)      | 18542 (28.1)      | >0.999| 3830 (16.4)      | 3830 (16.4)       | >0.999|
| ≥50                           | 47424 (71.9)      | 47424 (71.9)      |       | 19536 (83.6)     | 19536 (83.6)      |       |
| Monthly income (US Dollar, n [%]) |               |                   |       |                   |                   |       |
| 1–530                         | 26622 (40.4)      | 27292 (41.4)      | <0.001| 10735 (45.9)     | 10964 (46.9)      | 0.044 |
| 530–830                       | 23194 (35.2)      | 23585 (35.8)      |       | 8614 (36.9)      | 8361 (35.8)       |       |
| ≥830                          | 16150 (24.5)      | 15089 (22.9)      |       | 4017 (17.2)      | 4041 (17.3)       |       |
| Geographical region,* n [%]   |                   |                   |       |                   |                   |       |
| Northern                      | 28120 (42.6)      | 30977 (47.0)      | <0.001| 9290 (39.8)      | 10842 (46.4)      | <0.001|
| Central                       | 17073 (25.9)      | 14720 (22.3)      |       | 6878 (29.4)      | 5318 (22.8)       |       |
| Southern                      | 18870 (28.6)      | 18503 (28.1)      |       | 6457 (27.6)      | 6544 (28.0)       |       |
| Eastern                       | 1903 (2.9)        | 1766 (2.7)        |       | 741 (3.2)        | 662 (2.8)         |       |
| Urbanization level, n [%]     |                   |                   |       |                   |                   |       |
| 1 (most urbanized)            | 17864 (27.1)      | 19076 (28.9)      | <0.001| 5481 (23.5)      | 6535 (28.0)       | <0.001|
| 2                             | 18510 (28.1)      | 17922 (27.2)      |       | 6279 (26.9)      | 6035 (25.8)       |       |
| 3                             | 10519 (16.0)      | 10398 (15.8)      |       | 3724 (15.9)      | 3624 (15.5)       |       |
| 4                             | 10200 (15.9)      | 9889 (15.0)       |       | 4193 (17.9)      | 3750 (16.1)       |       |
| 5 (least urbanized)           | 8873 (13.5)       | 8681 (13.2)       |       | 3689 (15.8)      | 3422 (14.7)       |       |
| Comorbidities, n [%]          |                   |                   |       |                   |                   |       |
| Hypertension                  | 40195 (60.9)      | 12255 (18.6)      | <0.001| 15336 (65.6)     | 5113 (21.9)       | <0.001|
| Diabetes                      | 14401 (21.8)      | 7984 (12.1)       | <0.001| 5976 (25.6)      | 3072 (13.2)       | <0.001|
| Hyperlipidemia                | 17155 (26.0)      | 7640 (11.6)       | <0.001| 6467 (27.7)      | 2758 (11.8)       | <0.001|
| Obesity                       | 1302 (2.0)        | 582 (0.9)         | <0.001| 485 (2.1)        | 184 (0.8)         | <0.001|

aTaiwan, China
This population-based cohort study found no relationship between the PCa incidence and antiarrhythmic drug usage (including sodium channel blockers, potassium channel blockers, beta-blockers, calcium channel blockers, and digoxin). To our knowledge, very few studies have mentioned the association between PCa risk and prior use of sodium channel blockers or potassium channel blockers, even though ion channel blockers are considered to be new therapeutic strategies against PCa in some experimental studies. Most previous studies only investigated the connection between the risk of PCa and the use of beta-blockers, calcium channel blockers, or digoxin. In addition, relevant findings in the literature are still conflicting.

Our study showed no increased risk of subsequent PCa for sodium channel blocker users or potassium channel blocker users compared to their matched nonusers, respectively. The findings in our study are similar to two western studies. One population-based case–control study in Finland showed that sodium channel blockers and potassium channel blockers for arrhythmia did not have a PCa preventive effect.21 Another cohort study in the United Kingdom showed that the use of Class I antiarrhythmic drugs (sodium channel blockers for arrhythmia) was not associated with the risk of cancer (HR: 1.11, 95% CI: 0.98–1.24, P = 0.09).21

In addition, results of our study showed no relationship between the subsequent risk of PCa and the use of beta-blockers, calcium channel blockers, or digoxin. These findings are consistent with some previous studies. For instance, three cohort studies, one nested case–control study, and one meta-analysis consistently observed that beta-blocker use was not associated with PCa-specific mortality.22–24 A meta-analysis and some observational studies in the United States, Canada, and the United Kingdom all found that the use of calcium channel blockers did not increase the risk of PCa.25,26 Furthermore, abundant research in Finland, the United Kingdom, and Ireland found no clear association between digoxin use and PCa.27,28

Nonetheless, results of several studies are inconsistent with our findings. One recent meta-analysis reported that the use of beta-blockers was associated with a decreased PCa-specific mortality (HR: 0.85, 95% CI: 0.77–0.94).17 One case–control study and a population-based cohort study found that beta-blocker use and propranolol use (a type of beta-blocker) were related with a reduced risk of PCa.18,29 In addition, an American study using a self-administered questionnaire showed an inverse association between calcium channel blocker usage and PCa risk (HR: 0.55, 95% CI: 0.31–0.97).30 However, a slightly elevated PCa risk in calcium channel blocker users (HR: 1.08, 95% CI: 1.00–1.16) was observed in a meta-analysis which included six cohort studies and eight case–control studies.31 Furthermore, a mailed questionnaire cohort study mentioned that regular digoxin users had a lower PCa risk compared to nonusers (RR: 0.76, 95% CI: 0.61–0.95).32 Another case–control study in the United States also reported that digoxin use was negatively associated with PCa in patients with more frequent PSA testing in the prior 5 years (OR: 0.44, 95% CI: 0.20–0.98).33 These inconsistent findings in the previous literature may have been due to several methodological limitations. For example, using a case–control study design may contribute to a selection bias. A small sample size of a cohort study might cause an insufficient statistical power. In addition, lacking information of some potential confounders might affect the actual relationship between antiarrhythmic drug use and the subsequent risk of PCa.

Our study has a number of specific strengths. First, this retrospective cohort study used a large population-based dataset which is representative of the entire population from Taiwan, China. The characteristic of the LHID2005 could provide a sufficiently large sample size of the results and further minimize selection bias in this study. The use of this dataset may also have increased the statistical power to detect an association between antiarrhythmic drug use and the subsequent PCa risk. Second, this study was performed in Taiwan, China, and most selected patients were of Chinese ethnicity. Because ethnicity is considered a risk factor for PCa, the homogeneity of the ethnicity in the selected cohorts may have eliminated a possible confounding effect on the results.34

Nevertheless, several limitations still must be considered. First, the LHID2005 used in this study provides no information regarding dietary habits, body mass index, family history, etc., which are considered as potential risk factors for PCa.35 However, we have adjusted the patients’ obesity in order to eliminate the potential influence about body-mass index. Second, the PCa diagnoses in this study relied on administrative claims data and ICD-9 codes. These diagnoses might be less accurate than those made according to standardized diagnostic examinations. Third, medical records on the PCa grade and stage, including prostate biopsy, pathologic data, and tumor-node-metastasis (TNM) classification of malignant tumors, were not available in this dataset. The PCa stage and severity might have confounded the relationship between antiarrhythmic drug use and the PCa risk. Finally, this study did not evaluate the potential effects of the length or dose of antiarrhythmic drugs exposure. This factor might affect the findings in this study. Therefore, more studies are still warranted to identify the association between length of antiarrhythmic drug exposure and the following PCa risk.

AUTHOR CONTRIBUTIONS

LTK and CCH participated in the design of the study and drafted the manuscript. HCL performed the statistical analysis and helped to draft the manuscript. CYH conceived of the study, participated in its design and coordination, and drafted the manuscript. All authors read and approved the final manuscript.

COMPETING INTERESTS

All authors declare no competing interests.
Table 4: Incidence rates, hazard ratios, and 95% confidence intervals for prostate cancer among sampled patients during a 5-year follow-up period

| Category                        | Total sample (n=131,932) | Total sample (n=65,966) | Total sample (n=46,732) | Total sample (n=23,366) |
|---------------------------------|--------------------------|-------------------------|-------------------------|-------------------------|
| **Incidence rate per 1000 person-years** | **Crude HR (95% CI)**    | **Adjusted HR (95% CI)** | **Crude HR (95% CI)**    | **Adjusted HR (95% CI)** |
| **Users (n=7031)**              |                          |                         |                         |                         |
|                                 | 2.00 (1.89–2.11)         | 1.17 (1.09–1.15)        | 1.00 (0.94–1.15)        | 0.89 (0.84–0.95)         |
|                                 | *                        | **                       |                         |                         |
| **Nonusers**                    |                          |                         |                         |                         |
|                                 | 2.18 (1.92–2.46)         | 1.14 (1.06–1.23)        | 1.00 (0.94–1.06)        | 0.89 (0.84–0.95)         |

The adjusted HR was calculated by a Cox proportional hazard regression stratified by age group and the index year.

REFERENCES

1. Attard G, Parker C, Eeles RA, Schroder F, Tomlinis SA, et al. Prostate cancer. Lancet 2016; 387: 70–82.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079–92.
3. Grönborg H. Prostate cancer epidemiology. Lancet 2003; 361: 859–64.
4. Sikes RA, Walls AM, Brennen WN, Anderson JD, Choudhury-Mukherjee I, et al. Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin Prostate Cancer 2003; 2: 181–7.
5. Fraser SP, Grimes JA, Djamgoz MB. Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate 2000; 44: 61–76.
6. Abdul M, Hoosein N. Expression and activity of potassium ion channels in human prostate cancer. Cancer Lett 2002; 186: 99–105.
7. Shapovalov G, Skryma R, Pervarskaya N. Calcium channels and prostate cancer. Recent Pat Anticancer Drug Discov 2013; 8: 18–26.
8. Parikh AS, Coghlan MJ, Gopalakrishnan M, Shieh CC. Effects of intermediate-conductance Ca²⁺-activated K⁺ channel modulators on human prostate cancer cell proliferation. Eur J Pharmacol 2003; 471: 157–64.
9. Yildirim S, Altun S, Gumushan H, Patel A, Djamgoz MB. Voltage-gated sodium channel activity promotes prostate cancer metastasis in vivo. Cancer Lett 2012; 323: 58–61.
10. Rybalchenko V, Pervarskaya N, Van Coppenolle F, Legrand G, Lemonnier L, et al. Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K⁺ channel gating. Mol Pharmacol 2001; 59: 1376–87.
11. Juang HH, Lin YF, Chang PL, Tsui KH. Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor. J Urol 2010; 184: 2158–64.
12. Pouliot F, Wu L. Cardiac glycosides may affect prostate specific antigen levels. J Urol 2010; 184: 1831–2.
13. Roger S, Potier M, Vandier C, Besson P, Le Guenney JC. Voltage-gated sodium channels: new targets in cancer therapy? Curr Pharm Des 2006; 12: 3681–95.
14. Trepel JB. Ion channels as molecular targets in prostate cancer. Clin Prostate Cancer 2003; 2: 188–9.
15. Kaapu KJ, Ahti J, Tammela TL, Auvinen A, Murtola TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: a population-based case-control study. Int J Cancer 2015; 137: 1187–95.
16. Fairhurst C, Watt I, Martin F, Bland M, Brackenbury WJ. Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based study. Sci Rep 2015; 5: 16758.
17. Lu H, Liu X, Guo F, Tan S, Wang G, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. Onco Targets Ther 2015; 8: 985–90.
18. Chang PY, Huang WY, Lin CL, Huang TC, Wu YY, et al. Propranolol reduces cancer risk: a population-based cohort study. Medicine (Baltimore) 2015; 94: e1097.
19. Wright JL, Hansten PD, Stanford JL. Is digoxin use for cardiovascular disease associated with risk of prostate cancer? Prostate 2014; 74: 97–102.
20. Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, et al. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev 2004; 13: 255–9.
21. Kaapu KJ, Murtola TJ, Talala K, Taari K, Tammela TL, et al. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer 2016; 115: 1289–95.
22. Kaapu KJ, Murtola TJ, Maatatten L, Talala K, Taari K, et al. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. Cancer Causes Control 2016; 27: 157–64.
23. Grimaldi-Bensouda L, Klungel O, Kurz X, de Groot MC, Maciel Afonso AS, et al. Beta-blocker use and risk of prostate cancer among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. Cancer Causes Control 2016; 27: 157–64.
24. Beales MS, McCloskey KD, Mills IG, Stanford JL. Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. Cancer Epidemiol Biomarkers Prev 2016; 25: 2680–9.
25. Zhang P, Hu WL, Wang KH. Do calcium channel blockers appear to have a protective effect on the development of prostate cancer clinically? Urol Oncol 2016; 34: 242–3.
26. Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 2013; 73: 250–60.
27. Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. Cancer Epidemiol 2013; 37: 881–5.
28. Assayag J, Pollak MN, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. Eur J Cancer 2014; 50: 2383–45.
29. Cardwell CR, Coleman HG, Murray LJ, O’Sullivan JM, Powe DG. Beta-blocker use and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Cancer Epidemiol 2014; 38: 279–85.
30. Choi CH, Song T, Kim TH, Choi JK, Park JY, et al. Meta-analysis of the effects of...
beta blocker on survival time in cancer patients. *J Cancer Res Clin Oncol* 2014; 140: 1179–88.
31 Vezina RM, Lesko SM, Rosenberg L, Shapiro S. Calcium channel blocker use and the risk of prostate cancer. *Am J Hypertens* 1998; 11: 1420–5.
32 Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). *Cancer Causes Control* 2004; 15: 535–41.
33 Fan Y, Zhou Y, Gong D, Zou C. No evidence for increased prostate cancer risk among calcium channel blockers user. *Int J Cardiol* 2015; 201: 255–7.
34 Karasneh RA, Murray LJ, Hughes CM, Cardwell CR. Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study. *Pharmacoepidemiol Drug Saf* 2016; 25: 1099–103.
35 Flahavan EM, Sharp L, Bennett K, Barron TI. A cohort study of digoxin exposure and mortality in men with prostate cancer. *BJU Int* 2014; 113: 236–45.
36 Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shirm JS, et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. *Cancer Discov* 2011; 1: 68–77.
37 Crawford ED. Epidemiology of prostate cancer. *Urology* 2003; 62: 3–12.
38 Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. Human prostate cancer risk factors. *Cancer* 2004; 101: 2371–490.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©The Author(s)(2017)